Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANZ-521 in Hepatitis C
NCT00800007Phase 2Terminated
- Sponsor
- Anza Therapeutics
- Start
- Nov 2008
- Primary completion
- Feb 2009
- Modality
- Gene Editing, Microbiome Therapeutics, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of ANZ-521 in hepatitis C (HCV), sponsored by Anza Therapeutics. Started Nov 2008; status: terminated.
02
Drugs
ANZ-521
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00800007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00800007.